vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and Marygold Companies, Inc. (MGLD). Click either name above to swap in a different company.

Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $5.5M, roughly 1.4× IMMUCELL CORP). IMMUCELL CORP runs the higher net margin — -2.5% vs -7.5%, a 5.0% gap on every dollar of revenue. On growth, Marygold Companies, Inc. posted the faster year-over-year revenue change (-4.5% vs -8.4%). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -1.5%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.

ICCC vs MGLD — Head-to-Head

Bigger by revenue
MGLD
MGLD
1.4× larger
MGLD
$7.6M
$5.5M
ICCC
Growing faster (revenue YoY)
MGLD
MGLD
+3.9% gap
MGLD
-4.5%
-8.4%
ICCC
Higher net margin
ICCC
ICCC
5.0% more per $
ICCC
-2.5%
-7.5%
MGLD
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-1.5%
MGLD

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
ICCC
ICCC
MGLD
MGLD
Revenue
$5.5M
$7.6M
Net Profit
$-139.7K
$-576.0K
Gross Margin
42.9%
74.0%
Operating Margin
0.4%
-8.3%
Net Margin
-2.5%
-7.5%
Revenue YoY
-8.4%
-4.5%
Net Profit YoY
80.1%
67.0%
EPS (diluted)
$-0.02
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
MGLD
MGLD
Q4 25
$7.6M
Q3 25
$5.5M
$7.0M
Q2 25
$6.4M
$7.2M
Q1 25
$8.1M
$7.0M
Q4 24
$7.8M
$8.0M
Q3 24
$6.0M
$7.9M
Q2 24
$5.5M
$8.3M
Q1 24
$7.3M
$7.9M
Net Profit
ICCC
ICCC
MGLD
MGLD
Q4 25
$-576.0K
Q3 25
$-139.7K
$-356.0K
Q2 25
$501.9K
$-1.5M
Q1 25
$1.4M
$-1.0M
Q4 24
$-1.7M
Q3 24
$-701.7K
$-1.6M
Q2 24
$-1.5M
$-1.9M
Q1 24
$-437.9K
$-529.0K
Gross Margin
ICCC
ICCC
MGLD
MGLD
Q4 25
74.0%
Q3 25
42.9%
77.0%
Q2 25
43.7%
67.8%
Q1 25
41.6%
75.0%
Q4 24
36.5%
74.1%
Q3 24
26.3%
73.1%
Q2 24
22.5%
72.5%
Q1 24
31.6%
70.5%
Operating Margin
ICCC
ICCC
MGLD
MGLD
Q4 25
-8.3%
Q3 25
0.4%
-18.2%
Q2 25
8.8%
-16.5%
Q1 25
13.9%
-21.4%
Q4 24
8.0%
-22.8%
Q3 24
-9.6%
-27.4%
Q2 24
-25.3%
-33.3%
Q1 24
-4.1%
-18.7%
Net Margin
ICCC
ICCC
MGLD
MGLD
Q4 25
-7.5%
Q3 25
-2.5%
-5.1%
Q2 25
7.8%
-20.4%
Q1 25
17.9%
-14.4%
Q4 24
-21.8%
Q3 24
-11.7%
-20.1%
Q2 24
-28.0%
-22.5%
Q1 24
-6.0%
-6.7%
EPS (diluted)
ICCC
ICCC
MGLD
MGLD
Q4 25
$-0.01
Q3 25
$-0.02
$-0.01
Q2 25
$0.06
$-0.04
Q1 25
$0.16
$-0.02
Q4 24
$0.09
$-0.04
Q3 24
$-0.09
$-0.04
Q2 24
$-0.20
$-0.05
Q1 24
$-0.06
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
MGLD
MGLD
Cash + ST InvestmentsLiquidity on hand
$3.9M
$11.6M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$29.8M
$22.7M
Total Assets
$45.7M
$27.8M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
MGLD
MGLD
Q4 25
$11.6M
Q3 25
$3.9M
$12.5M
Q2 25
$12.8M
Q1 25
$15.6M
Q4 24
$3.8M
$14.9M
Q3 24
$17.5M
Q2 24
$1.3M
$15.0M
Q1 24
$960.3K
$16.1M
Total Debt
ICCC
ICCC
MGLD
MGLD
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
MGLD
MGLD
Q4 25
$22.7M
Q3 25
$29.8M
$22.9M
Q2 25
$29.9M
$23.0M
Q1 25
$29.0M
$24.3M
Q4 24
$27.5M
$23.4M
Q3 24
$26.4M
$25.5M
Q2 24
$23.5M
$26.6M
Q1 24
$24.6M
$28.4M
Total Assets
ICCC
ICCC
MGLD
MGLD
Q4 25
$27.8M
Q3 25
$45.7M
$28.4M
Q2 25
$46.7M
$30.4M
Q1 25
$45.6M
$33.5M
Q4 24
$45.1M
$33.0M
Q3 24
$44.4M
$35.9M
Q2 24
$41.9M
$32.9M
Q1 24
$43.1M
$33.7M
Debt / Equity
ICCC
ICCC
MGLD
MGLD
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
MGLD
MGLD
Operating Cash FlowLast quarter
$-1.2M
$-908.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
MGLD
MGLD
Q4 25
$-908.0K
Q3 25
$-1.2M
$-533.0K
Q2 25
$1.6M
$-3.3M
Q1 25
$1.6M
$-1.2M
Q4 24
$-3.1K
$-770.0K
Q3 24
$-639.3K
$-893.0K
Q2 24
$581.8K
$-1.9M
Q1 24
$418.5K
$-658.0K
Free Cash Flow
ICCC
ICCC
MGLD
MGLD
Q4 25
Q3 25
$-1.8M
$-562.0K
Q2 25
$1.4M
$-3.4M
Q1 25
$1.2M
Q4 24
$-199.3K
$-776.0K
Q3 24
$-727.7K
$-940.0K
Q2 24
$471.0K
$-2.0M
Q1 24
$348.1K
FCF Margin
ICCC
ICCC
MGLD
MGLD
Q4 25
Q3 25
-32.3%
-8.1%
Q2 25
22.4%
-46.8%
Q1 25
15.4%
Q4 24
-2.6%
-9.7%
Q3 24
-12.1%
-11.9%
Q2 24
8.6%
-23.8%
Q1 24
4.8%
Capex Intensity
ICCC
ICCC
MGLD
MGLD
Q4 25
0.0%
Q3 25
10.8%
0.4%
Q2 25
2.4%
0.7%
Q1 25
4.1%
0.0%
Q4 24
2.5%
0.1%
Q3 24
1.5%
0.6%
Q2 24
2.0%
0.7%
Q1 24
1.0%
0.0%
Cash Conversion
ICCC
ICCC
MGLD
MGLD
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ICCC
ICCC

Segment breakdown not available.

MGLD
MGLD

Fund Management Related Party$4.6M60%
Food Products$1.7M22%
Beauty Products$1.2M15%
Other$268.0K4%

Related Comparisons